Ashwagandha
Ashwagandha (winter cherry) is an Ayurvedic plant; human studies show improvements in stress, sleep, hormones, performance and cognition.
We evaluated 179 human studies on Ashwagandha, including 94 randomised controlled trials and 38 meta-analyses or systematic reviews; the controlled studies include 7,658 participants in total. As of 3 October 2026.
1. What Is Ashwagandha? Occurrence, Origin and Forms
Ashwagandha (Withania somnifera), also known as winter cherry, is a plant of the nightshade family and has been part of India's Ayurvedic medicine for centuries. Its most important constituents are considered to be the withanolides.
The plant grows in dry regions of India, the Middle East and Africa and is cultivated mainly in India. Mostly the roots are used, less often the leaves and berries.
Products include dried root powder and extracts made with water or water-alcohol mixtures, usually standardised to a certain withanolide content. Many studies use named extracts from the root or from root and leaf.
Forms and Preparations Studied
- Root powder
- Standardised root extracts, such as KSM-66 or Shoden
- Root-and-leaf extracts, such as Sensoril
- Preparations applied to skin and hair
- Combination products with ashwagandha – the other ingredients are named in each case
Not covered on this page:
- Multi-herb Ayurvedic formulas in which the ashwagandha content is not stated → Adaptogens
- Isolated withanolides such as withaferin A in laboratory and animal experiments
2. What Does Ashwagandha Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Stress and anxiety | mostly improved | high | 15 meta-analyses · 42 controlled · 16 other | 2,749 |
| Hormones and fertility | mostly improved | high | 11 meta-analyses · 23 controlled · 10 other | 1,441 |
| Sleep | mostly improved | high | 5 meta-analyses · 26 controlled · 13 other | 1,752 |
| Memory and concentration | mostly improved | high | 3 meta-analyses · 16 controlled · 5 other | 503 |
| Physical performance and muscle strength | mostly improved | high | 5 meta-analyses · 14 controlled · 7 other | 521 |
| Metabolism, blood sugar and weight | mostly improved | high | 6 meta-analyses · 8 controlled · 5 other | 329 |
| Thyroid | mostly no difference | moderate | 5 meta-analyses · 3 controlled · 3 other | 170 |
| Skin and hair | mostly improved | moderate | 0 meta-analyses · 4 controlled · 1 other | 61 |
| Other outcomes | mostly improved | high | 13 meta-analyses · 68 controlled · 39 other | 6,261 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Ashwagandha, Stress and Anxiety: Human Studies
Ashwagandha extracts lowered perceived stress more than placebo in several randomized controlled studies 47535678. Anxiety improved more than with placebo in several randomized controlled studies 4659757884. One meta-analysis confirmed advantages for perceived stress, anxiety and serum cortisol 10; another saw an advantage only for cortisol, not for perceived stress 11. Cortisol fell more than with placebo in several randomized controlled studies 537884, while in others there was no difference 4659129. Skin conductance and heart rate variability improved compared with placebo 59, as did the cortisol response to a stress test 74. Fatigue and recovery also improved in individual randomized controlled studies 85127, while another found no difference 129. Individual randomized controlled studies found no difference in perceived stress 94121124. Mainly standardized root extracts were studied, as well as root powder and extracts from root and leaf. The evidence is strong, but many studies are small and short, and the extract forms are inconsistent, so it remains open which preparation and dose work most reliably.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Ferreira et al. 2025 | systematic review · 9,005 participants | Ashwagandha supplementation; mostly 500–1000 mg per day | anxiety reduction: improved |
| 2 Coope et al. 2026 | systematic review · 2,317 participants | Standardised Ashwagandha root extract (SARE), root only; 125 to 600 mg/day; Single dose to 180 days; vs. Comparator groups in randomised trials | Cortisol: improved |
| 4 Fornalik et al. 2026 | meta-analysis · 1,706 participants | Oral ashwagandha supplementation (Withania somnifera); not reported; subgroups by withanolide content; vs. Placebo | Cortisol: improved (SMD =- 1.18, p < 0.04) |
| 7 Akhgarjand et al. 2022 | meta-analysis · 1,002 participants | Ashwagandha extract (supplementation); 300–600 mg/d for stress; up to 12,000 mg/d for anxiety; vs. Placebo | Anxiety level: improved (SMD: -1.55, 95% CI: -2.37, -0.74; p = .005); Stress level: improved (SMD: -1.75; 95% CI: -2.29, -1.22; p = .005) |
| 10 Arumugam et al. 2024 | meta-analysis · 558 participants | Ashwagandha formulations (not further specified); vs. Placebo | Perceived Stress Scale (PSS): improved (MD = -4.72, 95 % CI = [-8.45 to -0.99]); Hamilton Anxiety Scale (HAS): improved (MD = -2.19, 95 % CI = [-3.83 to -0.55]); Serum cortisol levels: improved (MD = -2.58, 95 % CI = [-4.99 to -0.16]) |
| 11 Albalawi et al. 2025 | meta-analysis · 488 participants | Ashwagandha (Withania somnifera), oral dose ≥250 mg/day; ≥250 mg/day; ≥2 weeks; vs. Control groups of included RCTs | Cortisol levels: improved (-1.16 µg/dL, 95% CI: -1.64 to -0.69, P < 0.001); Perceived stress (PSS): no difference (SMD = -0.355, 95% CI: -1.188 to 0.47; P = 0.40) |
| 12 Cheah et al. 2021 | meta-analysis · 400 participants | Ashwagandha extract; Subgroup ≥600 mg/day; Subgroup ≥8 weeks; vs. Placebo | Anxiety level: improved |
| 13 Fatima et al. 2024 | meta-analysis · 254 participants | Withania somnifera extracts; vs. Placebo | Hamilton Anxiety Scale (HAM-A): improved (MD = -5.96; [95% CI -10.34, -1.59]; P = 0.008; I2 = 98%) |
Further studies in this area: 18 20 23 25 26 31 34 38 43 44 46 47 49 50 51 52 53 54 56 59 65 67 68 71 72 74 75 76 77 78 80 82 83 84 85 87 88 94 98 101 108 109 114 117 121 122 124 127 129 130 139 140 151 152 154 156 160 161 162 165 166 171 172 174 177
Ashwagandha, Hormones and Fertility: Human Studies
In healthy men 5766 and in men with reduced sperm count 132, sperm values improved more with root extract than with placebo. Sexual function also improved more in men than with placebo in several randomized controlled studies 5766123. Testosterone rose more in men than with placebo in several randomized controlled studies 7886123129; a meta-analysis found the increase in men, not in women 4. In menopausal women, root extract alleviated complaints and lowered FSH and LH more than placebo 5876. A combination preparation of Ashwagandha with Shilajit, ginger, black pepper, Mucuna pruriens and Akarkara improved testosterone and cortisol in a controlled study 69, while a combination with Shatavari root extract showed no change in serum hormones 49. The findings apply to the form studied in each case, mostly standardized root extracts, and cannot be transferred to all preparations; long-term effects and the active ingredients responsible remain open.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Ferreira et al. 2025 | systematic review · 9,005 participants | Ashwagandha supplementation; mostly 500–1000 mg per day | sexual function: improved |
| 2 Coope et al. 2026 | systematic review · 2,317 participants | Standardised Ashwagandha root extract (SARE), root only; 125 to 600 mg/day; Single dose to 180 days; vs. Comparator groups in randomised trials | Testosterone: unclear |
| 4 Fornalik et al. 2026 | meta-analysis · 1,706 participants | Oral ashwagandha supplementation (Withania somnifera); not reported; subgroups by withanolide content; vs. Placebo | Testosterone in men: improved (MD = 57.43 ng/dl); Testosterone in women: no difference (MD = 5.09 ng/dl); Estradiol (E2): no difference |
| 5 Zhu et al. 2026 | meta-analysis · 1,249 participants | Ashwagandha supplementation (Withania somnifera); vs. Control (placebo or no supplementation) | Testosterone: improved (SMD = 0.33; 95% CI: 0.13-0.54; P = 0.001) |
| 6 Ahmadian et al. 2022 | systematic review · 1,218 participants | Withania somnifera roots and other herbal medicines; vs. various herbal medicines compared | treatment success in male infertility: improved (12 cases were effective in treating male infertility) |
| 18 Łuszczak et al. 2026 | systematic review | Standardized extracts of Withania somnifera and Rhodiola rosea; W. somnifera 120-1000 mg/day; R. rosea 290-1500 mg/day; 3-16 weeks; vs. Control groups of included RCTs | Hormonal changes: improved |
| 21 Tallon et al. 2026 | systematic review | Ashwagandha (Withania somnifera), unspecified; vs. no control group; narrative evidence assessment | Reproductive toxicity and abortifacient activity: unclear (remains inconclusive); Hormonal balance: no difference (no adverse effects); Reproductive health: no difference (no adverse effects) |
| 22 Roy et al. 2026 | systematic review | Ashwagandha (form not specified) | Sexual health and fertility: improved; Reproductive disorders (e.g. PCOS, sperm quality): improved |
Further studies in this area: 23 28 30 34 47 49 50 55 57 58 61 66 69 72 75 76 77 78 84 86 88 95 113 121 123 129 132 137 148 152 158 159 162 164 166 176
Ashwagandha and Sleep: Human Studies
In sleep problems, standardized root extracts of winter cherry showed better sleep quality, shorter sleep onset latency, longer sleep duration and higher sleep efficiency in several controlled studies 456582. The time awake after falling asleep also improved 4565. Daytime sleepiness decreased more in older people than under placebo 89; a systematic review considers ashwagandha root promising for insomnia 34. Randomized controlled trials also found better sleep quality for a sustained-release root extract 4753 and for the formulation Zenroot™ 59. For total time in bed, there was no difference 13. Some of the studies examined mixtures with melatonin 43, shatavari root extract 48 or Abelmoschus esculentus 51 or the addition to iron therapy in pregnancy 67. A controlled, non-randomized study was funded by the manufacturer 133. The strength of evidence is high, but the doses, extracts and treatment durations studied differ, and for root powder as well as preparations for application to skin and hair, reliable sleep data are lacking.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Ferreira et al. 2025 | systematic review · 9,005 participants | Ashwagandha supplementation; mostly 500–1000 mg per day | sleep quality: improved |
| 12 Cheah et al. 2021 | meta-analysis · 400 participants | Ashwagandha extract; Subgroup ≥600 mg/day; Subgroup ≥8 weeks; vs. Placebo | Overall sleep (quantity and quality): improved (Standardized Mean Difference -0.59; 95% Confidence Interval -0.75 to -0.42; I2 = 62%) |
| 13 Fatima et al. 2024 | meta-analysis · 254 participants | Withania somnifera extracts; vs. Placebo | Sleep Onset Latency (SOL): improved; Total Sleep Time (TST): improved; Pittsburgh Sleep Quality Index (PSQI): improved |
| 18 Łuszczak et al. 2026 | systematic review | Standardized extracts of Withania somnifera and Rhodiola rosea; W. somnifera 120-1000 mg/day; R. rosea 290-1500 mg/day; 3-16 weeks; vs. Control groups of included RCTs | Sleep quality: improved |
| 19 Kulkarni et al. 2026 | systematic review | Ayurvedic therapies including Ashwagandha; vs. no comparator in most studies | improvement of insomnia: improved |
| 25 Marchi et al. 2025 | systematic review | Withania somnifera (Ashwagandha); median 600 mg/day orally; one study Shirodhara; median 8 weeks follow-up; vs. any comparator (randomised controlled trials) | sleep quality (SMD): improved (SMD: -1.35 (95% CI: -1.79; -0.91)) |
| 34 Tandon et al. 2020 | systematic review | Ashwagandha root preparations | Efficacy in insomnia: improved |
| 43 Movva et al. 2026 | randomised controlled · 200 participants | Ashwagandha root extract (ARE), melatonin (MLT), combination, or placebo; ARE 300 mg twice daily; MLT 3 mg/day; combination ARE 600 mg/day + MLT 3 mg/day; eight weeks; vs. placebo; ARE monotherapy vs. MLT monotherapy vs. combination | sleep onset latency (SOL): improved (p < 0.0001); total sleep time (TST): improved (p < 0.0001); wake after sleep onset (WASO): improved (p < 0.0001) |
Further studies in this area: 45 47 48 50 51 53 59 65 67 68 80 81 82 83 89 104 108 109 114 116 117 124 125 128 133 147 151 153 154 160 161 162 165 166 172 174
Ashwagandha, Memory and Concentration: Human Studies
In several randomized controlled trials, ashwagandha extracts improved memory more than placebo, in healthy adults, in mild cognitive impairment and in children 538591104. Attention was also better in several controlled studies 8591105135. Working memory improved in several controlled studies 96104105135. Executive function was better than under placebo in several randomized controlled trials 91104109. Reaction time was better in several controlled studies 85104. Mental alertness was better in several controlled studies 6580128. A randomized controlled trial with a root-leaf extract with a liposomal coating found better results for word recall, image recognition and reaction time 85. A randomized controlled trial with a combination preparation of ashwagandha and piperine showed better multitasking and concentration performance 87. A randomized controlled trial with a combination preparation of ashwagandha and Andrographis paniculata found better attention and concentration performance 101. A meta-analysis found advantages for memory, attention, executive function and visuospatial abilities 5; a systematic review evaluates the studies as early indications 35. The studies examined predominantly adults, some with mild cognitive impairment, children and adolescents with ADHD as well as healthy older people. It remains open which ingredients and dosages are decisive for the effects.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 5 Zhu et al. 2026 | meta-analysis · 1,249 participants | Ashwagandha supplementation (Withania somnifera); vs. Control (placebo or no supplementation) | Memory: improved (SMD = 0.52; 95% CI: 0.27-0.78; P < 0.001); Attention and processing speed: improved (SMD = 0.29; 95% CI: 0.07-0.51; P = 0.009); Executive function: improved (SMD = -0.42; 95% CI: -0.70 to -0.13; P = 0.004) |
| 18 Łuszczak et al. 2026 | systematic review | Standardized extracts of Withania somnifera and Rhodiola rosea; W. somnifera 120-1000 mg/day; R. rosea 290-1500 mg/day; 3-16 weeks; vs. Control groups of included RCTs | Cognitive functions: improved |
| 34 Tandon et al. 2020 | systematic review | Ashwagandha root preparations | Memory and cognitive improvement: improved |
| 35 Ng et al. 2020 | systematic review | Withania somnifera (Ashwagandha) extract; vs. placebo (randomized, double-blind, placebo-controlled trials) | performance on cognitive tasks: improved; executive function: improved; attention: improved |
| 53 Gopukumar et al. 2021 | randomised controlled · 130 participants | Ashwagandha root extract 300 mg sustained-release capsule (Prolanza™, Ashwagandha SR); one capsule daily; 90 days; vs. placebo, double-blind, randomized | first attempt memory score: improved (12.9 ± 6.7 vs. 10.1 ± 6.3); total error rate in recalling patterns: improved (17.5 ± 23.3 vs. 27.7 ± 23.6) |
| 65 Langade et al. 2021 | randomised controlled · 80 participants | Ashwagandha root extract; 8 weeks; vs. Placebo | Mental alertness on rising: improved (p 0.01) |
| 80 Baker et al. 2022 | randomised controlled · 60 participants | Full spectrum ashwagandha root extract; 700 mg per day, one capsule twice daily; 30 days; vs. Placebo (glycerol capsules) | Perceived mental clarity: improved |
| 85 Leonard et al. 2024 | randomised controlled · 59 participants | Ashwagandha root and leaf extract with liposomal coating; 225 mg acutely and 225 mg/d for 30 days; 30 days; acute at 60 minutes; vs. Placebo (Gum Arabic), randomized double-blind | Word Recall (correct and recalled attempts): improved; Choice Reaction Time (targets identified): improved; Picture Recognition (yes correct responses, reaction time): improved |
Further studies in this area: 87 91 96 101 104 105 108 109 116 122 128 135 140 162 165 170
Ashwagandha, Physical Performance and Muscle Strength: Human Studies
With strength training, maximum strength increased more under ashwagandha extracts than under placebo in several randomized controlled trials 616286131. Maximum oxygen uptake as a measure of endurance increased more than under placebo in several randomized controlled trials 616292106127. Muscle circumference also increased more 6286, and creatine kinase as a marker of muscle stress decreased 86106; a randomized controlled trial with interval training found no difference in endurance 111. A meta-analysis found better muscle strength in physically active people, but no difference in untrained people 5, and a randomized controlled trial showed no difference in muscle soreness 99. A systematic review considers an additional benefit to strength training possible, but rates the certainty of evidence as low 16; many studies are small and short.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Ferreira et al. 2025 | systematic review · 9,005 participants | Ashwagandha supplementation; mostly 500–1000 mg per day | endurance and muscular strength: improved |
| 3 Wang et al. 2025 | meta-analysis · 2,062 participants | Withania somnifera (ashwagandha) among 14 other plant substances; vs. Standard treatment or other plant substances | Physical functioning: improved (SMD = 7.78, 95% CI: 6.61-8.96) |
| 5 Zhu et al. 2026 | meta-analysis · 1,249 participants | Ashwagandha supplementation (Withania somnifera); vs. Control (placebo or no supplementation) | Muscle strength: improved (SMD = 0.58; 95% CI: 0.12-1.04; P = 0.013); Muscle strength in physically active individuals: improved (SMD = 1.03; 95% CI: 0.56-1.49; P < 0.001); Muscle strength in untrained or special populations: no difference |
| 9 Li et al. 2026 | meta-analysis · 599 participants | Oral Withania somnifera (ashwagandha) supplementation; 500-600 mg/day most evidence-supported; vs. Placebo or control condition | Overall exercise performance: improved (Hedges' g = 0.47, 95% CI [0.25, 0.69], p < 0.001); Aerobic endurance: improved (g = 0.54, 95% CI [0.22, 0.85], p = 0.002); Strength performance: unclear |
| 15 Pérez-Gómez et al. 2020 | meta-analysis · 162 participants | Ashwagandha supplementation; vs. Control group (RCT) | Maximum oxygen consumption (VO2max): improved (p = 0.04) |
| 16 Lee et al. 2026 | systematic review · 161 participants | standardized ashwagandha extract (root or root-and-leaf); vs. placebo alongside resistance training | 1-RM bench press: improved (SMD 0.60, 95% CI 0.20-1.01); lower-body 1-RM: improved (0.52, 0.19-0.86) |
| 18 Łuszczak et al. 2026 | systematic review | Standardized extracts of Withania somnifera and Rhodiola rosea; W. somnifera 120-1000 mg/day; R. rosea 290-1500 mg/day; 3-16 weeks; vs. Control groups of included RCTs | Muscle strength and recovery: improved |
| 54 Tamoli et al. 2023 | randomised controlled · 103 participants | Smotect tablets, nicotine-free herbal blend containing Withania somnifera; 2 tablets twice daily; 90 days; vs. Placebo tablets | Energy and stamina levels: improved |
Further studies in this area: 61 62 69 86 89 92 99 106 111 116 118 127 131 142 157 160 162 166
Ashwagandha, Metabolism, Blood Sugar and Weight: Human Studies
In overweight and chronic stress, standardized root extracts improved body weight and body mass index in several randomized controlled trials 5688. Body composition also improved: a root extract lowered body fat percentage in young men with strength training 86, an aqueous extract of root and leaf (Sensoril®) improved the android/gynoid ratio in recreationally active men 131. In the lipid profile, triglycerides decreased under a standardized extract 75 and several cholesterol values under a mixture with Syzygium cumini 134; neither of the two summaries mentions a comparison with the control group. In a randomized controlled trial with interval training, lipids and body composition remained unchanged 113. A meta-analysis found no influence on body weight and body fat percentage 5, and milk enriched with tryptophan did not change body composition 117. Ashwagandha slightly lowered fasting blood glucose compared with placebo in a meta-analysis, with very low certainty of evidence 8.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 5 Zhu et al. 2026 | meta-analysis · 1,249 participants | Ashwagandha supplementation (Withania somnifera); vs. Control (placebo or no supplementation) | Body weight: no difference; Body fat percentage: no difference |
| 8 Farrin et al. 2026 | meta-analysis · 667 participants | Ashwagandha (Withania somnifera) supplementation; not reported; not reported; vs. Placebo | Fasting blood glucose: improved (WMD, -3.09 mg/dL; 95% CI, -5.61 to -0.58); HbA1c: unclear (WMD, -0.05%; 95% CI, -0.47 to 0.36) |
| 16 Lee et al. 2026 | systematic review · 161 participants | standardized ashwagandha extract (root or root-and-leaf); vs. placebo alongside resistance training | body fat: no difference (-0.32, -0.72-0.08) |
| 26 Quinones et al. 2025 | systematic review | Ashwagandha (form not specified) | Weight loss: improved; Leptin and insulin sensitivity: improved |
| 34 Tandon et al. 2020 | systematic review | Ashwagandha root preparations | Efficacy in type-2 diabetes: improved |
| 36 Durg et al. 2020 | systematic review | Withania somnifera (Indian ginseng), preparation not specified; vs. control/placebo in included studies | blood glucose (experimental data): improved (mean difference, -196.27; 95% confidence interval [-220.96, -171.58]; p < .00001); glycosylated haemoglobin (HbA1c): improved; insulin: improved |
| 56 Pakhale et al. 2025 | randomised controlled · 100 participants | Ashwagandha root extract (ARE); 300 mg twice daily; 24 weeks; vs. Placebo | Body weight: improved (-8.46 ± 3.86 kg); Body mass index: improved (-3.31 ± 1.57 kg/m2) |
| 75 Pattojoshi et al. 2026 | randomised controlled · 60 participants | Ashwagen®, standardized Withania somnifera extract, 300 mg capsule; 300 mg twice daily; 60 days; vs. Placebo, randomized, double-blind | Triglycerides: improved (13.00%); LDL: unclear (favorable trends in LDL) |
Further studies in this area: 86 88 113 117 131 134 137 143 152 166 169
Ashwagandha and Thyroid: Human Studies
For the thyroid, the studies show no uniform picture: a randomized controlled trial with root extract found an improvement in thyroid hormones in adults with subclinical hypothyroidism 90, and a systematic review reports more favorable values under ashwagandha than under placebo in primary hypothyroidism 14. This is contrasted by randomized controlled trials that found no difference in the thyroid hormone profile in healthy adults under standardized root extracts 6495. The strength of evidence is moderate: the findings are based predominantly on small studies and reviews with inconsistently named extracts, while the meta-analysis with the most participants saw an advantage only for T4, not for TSH and T3 4. Mainly root powder and standardized root extracts were studied; for specifically defined extracts such as KSM-66 or Shoden and for combination preparations, reliable data on thyroid function are lacking. It remains open whether and at which baseline values an effect exists. It also remains open whether risks arise in thyroid patients 158.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 4 Fornalik et al. 2026 | meta-analysis · 1,706 participants | Oral ashwagandha supplementation (Withania somnifera); not reported; subgroups by withanolide content; vs. Placebo | TSH: no difference; T3: no difference; T4: improved (MD = 0.61 µg/dL, p = 0.02) |
| 14 Javidi et al. 2023 | systematic review · 186 participants | Ashwagandha (extract not further specified); 4 and 8 weeks; vs. Placebo | T3 increase from baseline: improved (18.6% (p=0.012) and 41.5% (p < 0.001)); T4 increase from baseline: improved (9.3% (p= 0.002) and 19.6% (p < 0.001)); TSH decrease versus placebo: improved (p <0.001) |
| 21 Tallon et al. 2026 | systematic review | Ashwagandha (Withania somnifera), unspecified; vs. no control group; narrative evidence assessment | Thyroid function: no difference (no adverse effects) |
| 23 Vollmer et al. 2026 | systematic review | Ashwagandha (Withania somnifera) | thyroid hormones in hypothyroid contexts: improved |
| 34 Tandon et al. 2020 | systematic review | Ashwagandha root preparations | Efficacy in subclinical hypothyroidism: improved |
| 64 Verma et al. 2021 | randomised controlled · 80 participants | Ashwagandha root extract 300 mg; 300 mg twice daily, orally; 8 weeks; vs. Placebo of same dosage | Thyroid hormonal profile: no difference |
| 90 Sharma et al. 2018 | randomised controlled · 50 participants | Ashwagandha root extract (Withania somnifera); 600 mg daily; 8 weeks; vs. Placebo (starch) | Serum TSH: improved (p < 0.001); Serum T3: improved (p = 0.0031); Serum T4: improved (p = 0.0096) |
| 95 Vaidya et al. 2026 | randomised controlled · 40 participants | Standardized Ashwagandha root extract capsules, ≥5.00 mg withanolides (HPLC-PDA, USP-NF); 200 mg twice daily; 180 days; vs. Placebo, double-blind, randomized 1:1 | Thyroid hormone levels: no difference |
Further studies in this area: 155 158 159
Ashwagandha, Skin and Hair: Human Studies
In hair loss, a randomized controlled trial with a topical ashwagandha root extract serum showed higher hair density as well as less hair loss, more hair growth and greater hair thickness 73. A randomized controlled trial on a lotion with standardized ashwagandha root extract found a better physician's global assessment of the skin, lower water loss, more skin moisture and higher skin elasticity, while the melanin index remained unchanged 120. The strength of evidence is moderate; the studies are small, and the results apply in each case to the form and preparation studied.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 73 Yerram et al. 2023 | randomised controlled · 61 participants | Topical Ashwagandha root extract serum; 75 days; vs. Placebo (topical) | Hair shedding in 60 Seconds Hair Comb test: improved; Hair density: improved (7.3 vs. 2.8, P < 0.001); Hair growth: improved (21.7 vs. 4.2, P < 0.001) |
| 107 Jillella et al. 2026 | randomised controlled | Standardized Ashwagandha root extract capsule; 300 mg twice daily; 75 days; vs. Placebo | Transepidermal water loss (TEWL): improved; Hair density, growth, anagen, telogen, anagen:telogen ratio: improved (p < 0.05); Skin-specific quality of life (DLQI): improved (p < 0.05) |
| 120 Narra et al. 2023 | randomised controlled | Lotion with 8% standardized Ashwagandha root extract; 8% extract, topical, 60 days; 60 days; vs. Placebo lotion | Total physician assessment score: improved (-74.69%); Transepidermal water loss (TEWL): improved (-15.12%); Skin hydration: improved (20.66%) |
| 125 Maloh et al. 2022 | randomised controlled | InnerCalm (oral) and SuperCalm (topical), botanical ingredients incl. ashwagandha; 8 weeks; vs. Oral, topical, and combined groups; compared to baseline | Facial redness: improved (p < 0.001); Facial pigmentation: improved (p < 0.05) |
| 168 Ahmed et al. 2025 | review | Ashwagandha among other herbal hair loss remedies | hair growth in hair loss: unclear |
Ashwagandha: Further Outcomes in Studies
Mood and psychological well-being improved more under ashwagandha extracts than under placebo in several randomized controlled trials 46475359. Quality of life improved more than under placebo in several randomized controlled trials 5657618992; a meta-analysis on sleep, by contrast, found no influence on quality of life 12. In women, root extract improved sexual function more than placebo in several randomized controlled trials 637293. C-reactive protein decreased more than under placebo in frail older people 116, while two studies in schizophrenia found no difference in inflammatory markers 94130. In controlled studies, serious adverse events did not occur more frequently than under placebo 4064. However, a systematic review reports liver injuries in connection with ashwagandha-containing products, including multi-ingredient formulations 17. The findings apply to the form studied in each case, such as standardized root extracts, root powder or extracts of root and leaf; the robustness is high, while the transferability to other extracts and long-term safety remain open.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 2 Coope et al. 2026 | systematic review · 2,317 participants | Standardised Ashwagandha root extract (SARE), root only; 125 to 600 mg/day; Single dose to 180 days; vs. Comparator groups in randomised trials | Hepatic, renal, haematological, endocrine and cardiovascular biomarkers: no difference; Serious adverse events |
| 3 Wang et al. 2025 | meta-analysis · 2,062 participants | Withania somnifera (ashwagandha) among 14 other plant substances; vs. Standard treatment or other plant substances | Quality of life: improved (SMD = 4.66, 95% CI: 3.47-5.85); Role functioning: improved (SMD = 8.10, 95% CI: 6.89-9.32); Emotional functioning: improved (SMD = 5.71, 95% CI: 4.81 to 6.61) |
| 4 Fornalik et al. 2026 | meta-analysis · 1,706 participants | Oral ashwagandha supplementation (Withania somnifera); not reported; subgroups by withanolide content; vs. Placebo | Serotonin: improved (MD = 31.75 ng/ml, p < 0.01) |
| 12 Cheah et al. 2021 | meta-analysis · 400 participants | Ashwagandha extract; Subgroup ≥600 mg/day; Subgroup ≥8 weeks; vs. Placebo | Mental alertness on rising: improved; Quality of life: no difference |
| 16 Lee et al. 2026 | systematic review · 161 participants | standardized ashwagandha extract (root or root-and-leaf); vs. placebo alongside resistance training | chest circumference: improved (0.86, 0.41-1.31) |
| 17 McIntyre et al. 2026 | systematic review · 25 participants | single-ingredient ashwagandha products or multi-ingredient formulations containing ashwagandha; liver injury typically after weeks of use; vs. no control group, scoping review of case reports and case series | ashwagandha-associated liver injury: worsened (25 patients); acute liver failure requiring transplantation: worsened (one case); deaths among patients with pre-existing cirrhosis: worsened (three deaths) |
| 18 Łuszczak et al. 2026 | systematic review | Standardized extracts of Withania somnifera and Rhodiola rosea; W. somnifera 120-1000 mg/day; R. rosea 290-1500 mg/day; 3-16 weeks; vs. Control groups of included RCTs | Depressive symptoms: improved |
| 20 Alsanie et al. 2026 | meta-analysis | Ashwagandha (Withania somnifera) supplements; Dose-response analysis of administered dosages; vs. Control groups of included RCTs | Depression (SMD): improved (SMD = -5.68; 95 % CI: -8.43 to -2.94) |
Further studies in this area: 24 25 26 27 29 30 32 33 34 36 37 39 40 41 42 44 45 46 47 48 49 50 51 53 54 55 56 57 58 59 60 61 63 64 67 68 70 72 73 74 75 76 77 79 80 87 88 89 92 93 94 95 97 100 101 102 103 105 109 110 111 112 114 115 116 117 118 119 120 121 123 124 125 126 127 128 129 130 131 133 136 137 138 139 140 141 142 144 145 146 148 149 150 151 152 154 155 158 159 160 161 162 163 165 166 167 169 172 173 174 175 176
4. How Is Ashwagandha Dosed? Preparation, Dose and Duration in Studies
The studies predominantly used standardized root extracts, some named specifically such as KSM-66, Shoden, AshwaSR, Prolanza or Witholytin. In addition, root powder and extracts from root and leaf were used, such as Sensoril. For skin and hair, a topical root extract serum and a lotion with standardized root extract were tested; some of the studies investigated combination preparations whose other ingredients are named in each case.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| Standardized Ashwagandha root extract (500 mg aqueous root extract) orally | 500 mg daily | up to week 28, monitoring every 4 weeks | 39 |
| Ashwagandha root extract (ARE) | 600 mg/day in two divided doses | 8 weeks | 40 |
| Withania somnifera (WS), oral | 500 mg for 12 weeks | 12 weeks | 41 |
| BV-4051, polyherbal Ayurvedic formulation (Ashwagandha, Boswellia, Ginger, Turmeric) | — | 14 days | 42 |
| Ashwagandha root extract (ARE), melatonin (MLT), combination, or placebo | ARE 300 mg twice daily; MLT 3 mg/day; combination ARE 600 mg/day + MLT 3 mg/day | eight weeks | 43 |
| Withania somnifera (WS, Ashwagandha) | — | 8 weeks (interim analysis of a 16-week study) | 44 |
| standardized ashwagandha extract (Shoden®) | 120 mg once daily | six weeks | 45 |
| Proprietary ashwagandha root extract (APB) vs. ashwagandha root extract (ARE) vs. placebo | 300 mg APB twice daily | 8 weeks | 46 |
| Ashwagandha root extract sustained-release (AshwaSR) capsules | 150 mg or 300 mg once daily | 60 days | 47 |
| Shatavari root extract with Ashwagandha root extract (SHT-ARE) | — | 8 weeks | 48 |
| Ashwagandha root extract combined with Shatavari root extract (ARE-SHT) | — | 8 weeks | 49 |
| Ashwagandha root extract sustained-release capsules (AshwaSR) | 150 mg or 300 mg once daily | 60 days | 50 |
| CL18100F4, blend of Withania somnifera root and Abelmoschus esculentus fruit extracts | 300 or 500 mg daily | 60 days | 51 |
| Aqueous Withania somnifera root and leaf extract (WS) | 125, 250 or 500 mg/day | 8 weeks | 52 |
| Ashwagandha root extract 300 mg sustained-release capsule (Prolanza™, Ashwagandha SR) | one capsule daily | 90 days | 53 |
5. Is Ashwagandha Safe? Side Effects in Studies
Controlled studies reported no differences in liver, kidney and blood values or in serious adverse events 22534394064. Mild and temporary complaints such as gastrointestinal complaints, headache, drowsiness or soft stool were frequently mentioned 2343940. However, a systematic review reports liver injuries in connection with Ashwagandha-containing products, including multi-ingredient formulations 17.
| Study | Reported side effects |
|---|---|
| 2 Coope et al. 2026 | Mild gastrointestinal discomfort, headache, transient drowsiness; no serious events |
| 3 Wang et al. 2025 | Withania somnifera reduced treatment side effects (fatigue, pain, nausea) |
| 6 Ahmadian et al. 2022 | no serious side effects reported |
| 8 Farrin et al. 2026 | not reported |
| 10 Arumugam et al. 2024 | Mild to moderate adverse events in four studies |
| 12 Cheah et al. 2021 | No serious side effects reported; safety data limited |
| 13 Fatima et al. 2024 | Safety assessed, no details in abstract |
| 17 McIntyre et al. 2026 | cholestatic/mixed hepatitis, jaundice, pruritus; 1 acute liver failure requiring transplantation, 3 deaths in pre-existing cirrhosis |
| 21 Tallon et al. 2026 | no adverse effects on thyroid, hormones, or reproduction reported |
| 25 Marchi et al. 2025 | no significant difference in safety and tolerability |
| 29 Diantini et al. 2023 | Safety of plants confirmed; interactions with remdesivir, favipiravir, lopinavir, ritonavir noted |
| 30 Gómez et al. 2023 | No serious adverse events reported |
6. What Remains Open: Limits of the Evidence
- Many studies are small and short; treatment durations differ considerably.
- The extracts studied have inconsistent compositions, so it remains open which preparation and dose work most reliably.
- For root powder and for preparations for application to skin and hair, robust data are lacking for several endpoints.
- The fertility findings come from men; corresponding studies for women are still pending.
- Long-term safety, especially for the liver, has not been clarified.
7. Bottom Line: What Is Established About Ashwagandha
Ashwagandha has been studied in numerous controlled human studies as root powder, as standardized root extract and as extract from root and leaf. Improvements in stress and anxiety, sleep quality, sperm parameters and sexual function, and physical performance and cognitive abilities are best supported. For body weight and blood sugar, the findings are mixed, and the data on the thyroid show no uniform picture.
The results apply in each case to the form and preparation studied and cannot readily be transferred to other extracts. Many studies are small and short, and some of the evidence comes from combination preparations. Tolerability was mostly unremarkable in the controlled studies, but a systematic review reports liver injuries in connection with Ashwagandha-containing products.
Frequently Asked Questions
How well has Ashwagandha been studied in humans?
We evaluated 179 human studies on Ashwagandha, including 94 randomised controlled trials and 38 meta-analyses or systematic reviews; the controlled studies include 7,658 participants in total. As of 3 October 2026.
Does Ashwagandha help with stress and anxiety? What the studies show
Does Ashwagandha help with hormones and fertility? What the studies show
Does Ashwagandha help with sleep? What the studies show
Does Ashwagandha help with memory and concentration? What the studies show
Does Ashwagandha help with physical performance and muscle strength? What the studies show
Does Ashwagandha help with metabolism, blood sugar and weight? What the studies show
Which forms of Ashwagandha were studied in human studies?
Mainly standardized root extracts were studied, some named specifically such as KSM-66, Shoden, AshwaSR, Prolanza or Witholytin. In addition, root powder and extracts from root and leaf were used, such as Sensoril. For skin and hair, a topical root extract serum and a lotion with standardized root extract were tested.
How good is the evidence for stress and anxiety?
For stress and anxiety, numerous controlled studies are available; a meta-analysis and a systematic review showed improvements 1038. Anxiety improved more than with placebo in several randomized controlled studies 46757884. However, individual randomized controlled studies found no difference in perceived stress 94121124.
Do the studies show effects on sleep?
Is there evidence of effects in men and women?
How tolerable is Ashwagandha in the studies?
Controlled studies reported no differences in liver, kidney and blood values or in serious adverse events 22534394064. Mild and temporary complaints such as gastrointestinal complaints, headache, drowsiness or soft stool were frequently mentioned 2343940. However, a systematic review reports liver injuries in connection with Ashwagandha-containing products, including multi-ingredient formulations 17.
Sources
- 1Ferreira JF, Ferreira RM, Maia F, Fernandes LG, Leão C, Pimenta N · 2025
- 2Coope OC, Willems MET, Levington A, Tallon MJ, Roman-Viñas B, Spurr TJ · 2026
- 3Wang L, Xu X, Guo M, Dong Y, Ding H, Hao S et al. · 2025
- 4Fornalik M, Malkiewicz A, Adamczak D, Nawrocki F, Zielinska A, Mondal SA · 2026
- 5
- 6Ahmadian M, Salari R, Noras MR, Bahrami-Taghanaki HR · 2022
- 7Akhgarjand C, Asoudeh F, Bagheri A, Kalantar Z, Vahabi Z, Shab-Bidar S et al. · 2022
- 8Farrin N, Nikparast A, Yadegari M, Sohrabnavi A, Pourreza S, Sohouli MH et al. · 2026
- 9
- 10Arumugam V, Vijayakumar V, Balakrishnan A, B Bhandari R, Boopalan D, Ponnurangam R et al. · 2024
- 11
- 12Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R · 2021
- 13Fatima K, Malik J, Muskan F, Raza G, Waseem A, Shahid H et al. · 2024
- 14Javidi N, Khorasani ZM, Salari R, Niroumand S, Yousefi M · 2023
- 15Pérez-Gómez J, Villafaina S, Adsuar JC, Merellano-Navarro E, Collado-Mateo D · 2020
- 16
- 17McIntyre D, Nguyen P, Kim Y, Meyer B, Salloum M · 2026
- 18
- 19Kulkarni SP, Parwe S, Kulkarni PS, Tonde SS · 2026
- 20Alsanie SA, Alhodieb FS, Askarpour M · 2026
- 21Tallon MJ, Koturbash I, Blum JL · 2026
- 22Roy D, Ghosh M, Roy D, Sharma N, Bhatia R, Rangra NK · 2026
- 23Vollmer G, Brendler T · 2026
- 24Brendler T, Rattray RD · 2026
- 25Marchi M, Grenzi P, Travascio A, Uberti D, De Micheli E, Quartaroli F et al. · 2025
- 26Quinones D, Barrow M, Seidler K · 2025
- 27Lerose V, Ponticelli M, Benedetto N, Carlucci V, Lela L, Tzvetkov NT et al. · 2024
- 28Morgado A, Tsampoukas G, Sokolakis I, Schoentgen N, Urkmez A, Sarikaya S · 2024
- 29Diantini A, Febriyanti RM, Levita J · 2023
- 30Gómez Afonso A, Fernandez-Lazaro D, Adams DP, Monserdà-Vilaró A, Fernandez-Lazaro CI · 2023
- 31Lorca C, Mulet M, Arévalo-Caro C, Sanchez MÁ, Perez A, Perrino M et al. · 2023
- 32Singh RS, Singh A, Kaur H, Batra G, Sarma P, Kaur H et al. · 2021
- 33Analysis of Clinical Trial Registry of India for Evidence of Anti-Arthritic Properties of Withania somnifera (Ashwagandha)Kanjilal S, Gupta AK, Patnaik RS, Dey A · 2021
- 34Tandon N, Yadav SS · 2020
- 35Ng QX, Loke W, Foo NX, Tan WJ, Chan HW, Lim DY et al. · 2020
- 36
- 37Brunetti P, Lo Faro AF, Tini A, Busardò FP, Carlier J · 2020
- 38Pratte MA, Nanavati KB, Young V, Morley CP · 2014
- 39Chopra A, Chaudhuri S, Gundeti MS, Sarmukaddam S, Tillu G, Chavan-Gautam P et al. · 2026
- 40Pakhale K, Salve J, Ademola J, Parraca J, Langade D · 2026
- 41Kulkarni-Munshi R, Talmohite D, More A, Chakravarty J, Kamat S, Khobragade A et al. · 2025
- 42Chitre D, Nadkarni S, Jagtap N, Tulle R, Gitte A, Rahate P et al. · 2023
- 43Movva N, Salve J, Wankhede K, Thakare V, Langade D · 2026
- 44Chopra A, Srikanth N, Patwardhan B, AYUSH CCRAS Research Group · 2021
- 45Deshpande A, Irani N, Balkrishnan R, Benny IR · 2020
- 46West RE, Biswas A, Rao R, Tayade H, Ademola J · 2026
- 47Thanawala S, Shah R, Alluri KV, Bhupathiraju K, Desomayanandanam P, Bhuvenendran A · 2026
- 48
- 49Ademola J, Ajgaonkar A, Debnath T, Debnath K, Langade J · 2025
- 50Thanawala S, Shah R, Bhupathiraju K, Venkata Alluri K, Desomayanandanam P, Bhuvenendran A · 2025
- 51Singh G, Dixit I, Kalman D, Gogineni NT · 2024
- 52Pandit S, Srivastav AK, Sur TK, Chaudhuri S, Wang Y, Biswas TK · 2024
- 53Gopukumar K, Thanawala S, Somepalli V, Rao TSS, Thamatam VB, Chauhan S · 2021
- 54Tamoli SM, Harit MK, Mundhe N, Pande SP, Damle N, Chavan S et al. · 2023
- 55Mutha AS, Mutha SA, Tejuja AH, Beldar AS, Mulay AM, Langade D · 2025
- 56Pakhale K, Pakhale R, Srivathsan M, Langade J, Langade D · 2025
- 57Mutha A, Beldar A, Mulay A, Tejuja A, Mutha S, Langade D · 2023
- 58Gopal S, Ajgaonkar A, Kanchi P, Kaundinya A, Thakare V, Chauhan S et al. · 2021
- 59Mahadevan M, Gopukumar K, Gupta R, Morde A, Patni P, Srinivas SS et al. · 2025
- 60
- 61Thanawala S, Shah R, Lopes A, Rudrappa G, Desomayanandanam P, Srinivas S · 2026
- 62
- 63
- 64Verma N, Gupta SK, Tiwari S, Mishra AK · 2021
- 65
- 66
- 67
- 68Majeed M, Nagabhushanam K, Murali A, Vishwanathan DT, Mamidala RV, Mundkur L · 2024
- 69Darshani Mohan, Subhashree Aparimita, Supriya H. Raut* · European Journal Pharmaceutical and Medical Research · 2025
- 70Effects of a standardized extract of Withania somnifera (Ashwagandha) on depression and anxiety symptoms in persons with schizophrenia participating in a randomized, placebo-controlled clinical trialGannon JM, Brar J, Rai A, Chengappa KNR · 2019
- 71
- 72Mutha AS, Mutha SA, Tejuja AH, Langade DK · 2024
- 73
- 74Lopresti AL, Smith SJ, Bethapudi B, R AA, Mundkinajeddu D, D'Souza P et al. · 2026
- 75Pattojoshi A, Kumar Patra S, Idrees SA, Behera S, Dalua SS, Tiwari P et al. · 2026
- 76
- 77
- 78
- 79Singh H, Yadav B, Rai AK, Srivastava S, Saiprasad A, Jameela S et al. · 2023
- 80Baker C, Kirby JB, O'Connor J, Lindsay KG, Hutchins A, Harris M · 2022
- 81
- 82Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D · 2019
- 83Salve J, Pate S, Debnath K, Langade D · 2019
- 84Lopresti AL, Smith SJ, Malvi H, Kodgule R · 2019
- 85Leonard M, Dickerson B, Estes L, Gonzalez DE, Jenkins V, Johnson S et al. · 2024
- 86Wankhede S, Langade D, Joshi K, Sinha SR, Bhattacharyya S · 2015
- 87
- 88Choudhary D, Bhattacharyya S, Joshi K · 2017
- 89
- 90
- 91Choudhary D, Bhattacharyya S, Bose S · 2017
- 92Choudhary B, Shetty A, Langade DG · 2015
- 93Dongre S, Langade D, Bhattacharyya S · 2015
- 94Marder SR, Marder SR, Kelly DL, DeVera G, Zaranski JO, Whelan F et al. · 2026
- 95Vaidya N, Agarwal R, Kshirsagar P, Ganu G, Nagore D, Mehta A et al. · 2026
- 96
- 97Pohl F, Dominique A, Dufour J, Wang J, Lin XL, Sharif B et al. · 2025
- 98Fuladi S, Emami SA, Mohammadpour AH, Karimani A, Manteghi AA, Sahebkar A · 2021
- 99Ferreira JF, Maia F, Ferreira RM, Martinho DV, Fernandes LG, Leão C et al. · 2026
- 100Ramapalaniappan A, Loganathan V, Morde A, Padigaru M, Patni P, Joshua L et al. · 2025
- 101Dimpfel W, Schombert L, Keplinger-Dimpfel IK, Panossian A · 2020
- 102
- 103Kim SK, Venkatesan J, Rathi P, Antony B · 2023
- 104Saxena A, Lopresti A, Sharif M, Elon N, Suri R, Langade DK · 2026
- 105Kale S, Lopresti A, Suri R, Garg N, Langade D · 2026
- 106Prajapati H, Satia M, Shah D, Basera I, Shah T · 2026
- 107Jillella A, Keerthi N, Venkateswar Reddy J · 2026
- 108McKinney E, Stewart J, Kewalramani R, Singh S · 2026
- 109Naik S, Muralidhar G, Rao BS, Agarwal S, Jain M · 2026
- 110Yousefi-Mohammadabad H, Abbasifard M, Haji-Maghsoudi S, Raeiszadeh M, Karegar-Borzi H · 2026
- 111Ewa J, Klusiewicz A, Rębiś K, Długołęcka B, Charmas M, Cieśliński I · 2025
- 112
- 113Charmas M, Jówko E, Długołęcka B, Klusiewicz A, Przybylska I, Galczak-Kondraciuk A · 2025
- 114Punukollu RS, Chadalawada AK, Siddabattuni K, Gogineni NT · 2024
- 115Pérez-Piñero S, Muñoz-Carrillo JC, Echepare-Taberna J, Luque-Rubia AJ, Millán Rivero JE, Muñoz-Cámara M et al. · 2024
- 116
- 117Pérez-Piñero S, Muñoz-Carrillo JC, Echepare-Taberna J, Muñoz-Cámara M, Herrera-Fernández C, Ávila-Gandía V et al. · 2024
- 118Raut A, Tripathi R, Marathe PA, Uchil DA, Agashe S, Rege N et al. · 2024
- 119Sadhupati DP, Lakshmisudha R, Chakravarthy KNK, Naidana PS · 2024
- 120Narra K, Naik SK, Ghatge AS · 2023
- 121
- 122Remenapp A, Coyle K, Orange T, Lynch T, Hooper D, Hooper S et al. · 2022
- 123Chauhan S, Srivastava MK, Pathak AK · 2022
- 124O'Connor J, Lindsay K, Baker C, Kirby J, Hutchins A, Harris M · 2022
- 125Maloh J, Chakkalakal M, Sulaiman F, Burney W, Chambers CJ, Sivamani RK · 2022
- 126Tharakan A, Shukla H, Benny IR, Tharakan M, George L, Koshy S · 2021
- 127
- 128Kelgane SB, Salve J, Sampara P, Debnath K · 2020
- 129
- 130Chengappa KNR, Brar JS, Gannon JM, Schlicht PJ · 2018
- 131Ziegenfuss TN, Kedia AW, Sandrock JE, Raub BJ, Kerksick CM, Lopez HL · 2018
- 132Ambiye VR, Langade D, Dongre S, Aptikar P, Kulkarni M, Dongre A · 2013
- 133Efficacy of Different Concentrations of Withanolides in Ashwagandha Supplements for Insomnia and Enhancing Energy Level· 2022
- 134Zubair K, Zafar F, Saif S, Khaliq U, Syed H, Sarfraz A et al. · 2026
- 135Xing D, Yoo C, Gonzalez D, Jenkins V, Nottingham K, Dickerson B et al. · 2022
- 136Likhitsup A, Chen VL, Fontana RJ · 2024
- 137Salve J, Kale S, Prajapati BL, Sparavigna A, Savant M, Ademola J et al. · 2026
- 138Movva N, Salve J, Debnath K, Thakare V, Langade D · 2026
- 139Pages-García C, De Almagro MC, Ruiz-Moreno J, De Castellar R · 2024
- 140Evaluation of Self-Reported Stress Reduction from Ashwagandha and B Vitamin Supplementation Using Ecological Momentary Assessment (EMA)Li I, Pacanowski C, Cao L, Chai S · 2020
- 141Vaidya VG, Naik NN, Ganu G, Parmar V, Jagtap S, Saste G et al. · 2024
- 142Vaidya VG, Gothwad A, Ganu G, Girme A, Modi SJ, Hingorani L · 2024
- 143
- 144Heo JU, Rao S, Newton HB, Dowlati A, Muzic RF, Kardan A · 2026
- 145Philips CA, Philips CA, Valsan A, Theruvath AH, Ravindran R, Oommen TT et al. · 2023
- 146Pérez Pérez S, Zumaqué-Valverde E, Saavedra Chacón MF, Arteta Cueto AA · 2026
- 147Wani KR, Ansari AN, Nayab M · 2026
- 148Javid J, Kunnuru SR, Anne B, Muskan S · 2026
- 149Speers AB, Limoico ED, Lozano-Ortiz A, Marney L, Choi J, Barr SA et al. · 2026
- 150Singh M, Garg P, Thakur R · 2026
- 151Effects of Four-Week Supplementation of Ashwagandha and B-Vitamins on Mood and Stress ReliefChai S, Li I, Pacanowski C, Brewer B · 2020
- 152Namysł M, Matczak S, Dachowska S, Haraj J, Majcherek E, Sobkowiak M et al. · 2026
- 153Vendrame M, Chai V · 2026
- 154Căuș MN, Lupoae M, Chițescu CL · 2026
- 155
- 156Zbozinek TD, Khalsa SS, Craske MG · 2026
- 157
- 158Kumar A, Sah BK, Ahmad F, Jamwal V, Sahu SK · 2026
- 159Li L, Zhang X, Hao J, Tian X, Zhu Y, Yang Y et al. · 2026
- 160AKbulut B, Canbolat E · 2026
- 161Pandey S, Pant P, Corbioli G, Bonazzi E, Cisneros-Yupanqui M, Salmaso P et al. · 2026
- 162
- 163Al Obaidi G, Saleeby Y, Varon J, Durzynski N, Tuszynki J, Halma M · 2026
- 164Skrzypiec-Spring M, Pokrywka A, Kuliczkowska-Płaksej J, Szeląg A, Bolanowski M · 2025
- 165Ashwagandha as an Adaptogenic Herb: A Comprehensive Review of Immunological and Neurological EffectsJamnekar PP, Dehankar TJ, Bedre RV, Dharan BG, Agravat B, Agravat H · 2025
- 166Sprengel M, Laskowski R, Jost Z · 2025
- 167Carty J, Navarro VJ · 2025
- 168Ahmed A, Alali AM, Abdullah E, Alharbi MN, Alayoubi HM · 2025
- 169Wiciński M, Fajkiel-Madajczyk A, Kurant Z, Liss S, Szyperski P, Szambelan M et al. · 2024
- 170Moise G, Jîjie AR, Moacă EA, Predescu IA, Dehelean CA, Hegheș A et al. · 2024
- 171Byrne GJ · 2023
- 172D'Cruz M, Andrade C · 2022
- 173Paul S, Chakraborty S, Anand U, Dey S, Nandy S, Ghorai M et al. · 2021
- 174Speers AB, Cabey KA, Soumyanath A, Wright KM · 2021
- 175Woo SM, Davis WD, Aggarwal S, Clinton JW, Kiparizoska S, Lewis JH · 2021
- 176Sengupta P, Agarwal A, Pogrebetskaya M, Roychoudhury S, Durairajanayagam D, Henkel R · 2018
- 177Wagner H, Nörr H, Winterhoff H · 1994
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.